Levetiracetam and Lacosamide in epilepsy patients
Introduction Conventional anti‑epileptic first‑line drugs can control the seizures of most patients with epilepsy, but persistent seizures occur in more than 30% of patients. Lacosamide, an antiepileptic drug, has been used as an adjuvant treatment for partial or systemic epilepsy. Objective To evaluate the therapeutic effect of levetiracetam combined with Lacosamide in patients with epilepsy. […]
Management of drug-resistant focal epilepsy with Levetiracetam
Introduction Epilepsy affects over 70 million people worldwide. With the evolving resistance of focal epilepsy, there is need for add-on therapies for better clinical outcomes. Objectives To evaluate the effectiveness of levetiracetam as an add-on treatment for people with drug-resistant focal epilepsy. Search methods The Cochrane Register of Studies (CRS Web, which includes the Cochrane […]
Hypolipidemia is associated with the severity of COVID-19
A study investigated pathological alteration in plasma lipid levels of COVID-19 patients. LDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects. Significant and gradual decreases in levels of LDL-c and TC were observed in all patients. HDL-c levels only decreased significantly in critical cases as compared with levels in […]
Treatment Tips as COVID-19 Complicates CVD Management in Diabetes
COVID-19 and related cardio-renal-pulmonary damage can profoundly affect the cardiovascular risk management of people with diabetes. It is recommended to continue ACE inhibitors and angiotensin receptor blockers, both SGLT2 inhibitors and GLP-1 receptor agonists have anti-inflammatory activities, which might be beneficial for patients with COVID-19. However, several expert groups in diabetes have previously advised that […]
Cardiovascular disease and COVID-19
Respiratory illness is the dominant clinical manifestation of COVID-19; CVD involvement occurs rarely. Acute cardiac injury, defined as a significant elevation of cardiac troponins, is the most commonly reported cardiac abnormality in COVID-19 affecting ~8–12% of patients. A Chinese study reported the incidence of heart failure in 52% of COVID-19 patients who subsequently died and […]
Multiple Sclerosis to Have Milder COVID-19 Symptoms?
A cross-sectional study conducted on 543 Multiple Sclerosis patients suggested that most Multiple Sclerosis patients developed a mild course of COVID-19 infection. The study was conducted to identify suspected COVID-19 cases and associated factors in Multiple Sclerosis patients by interrogation over phone and evaluating the medical records. Common symptoms suspicious for COVID-19 infection included dyspnea, […]